AddedRisk Factors
● Obudanersen, if approved, could face competition from commercial competitors in the future, including oral products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
For details regarding medicines that compete or may compete directly with our marketed medicines and late-stage medicines, refer to the section titled, Competition, in Part I, Item 1, Business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
For example, while we continue to activate sites in the U.S., Canada, U.K., Australia and Japan, we revised and resubmitted the study protocol for the REVEAL study of obudanersen to address changes requested by EU regulators and plan to initiate EU sites for this study in 2026. Importantly, we believe we are on track to complete enrollment for this study in 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, our development and commercialization activities could be harmed or delayed by staffing shortages or a shutdown or other significant disruption of the U.S. government, including the FDA or the U.S. PTO.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional inquiries, legislation and executive orders designed to, among other things, reduce drug prices, increase competition (including by enhancing support for generic and biosimilar drugs), lower out-of-pocket drug costs for patients, curtail spread pricing practices by pharmacy benefit managers, and foster scientific innovation to promote better health care and improved health. In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs. The IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics that have been on the market for at least seven years covered under Medicare, or the Medicare Drug Price Negotiation Program, and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. Under this program, HHS has already announced the agreed-upon prices of the first drugs that were subject to price negotiations and will announce the agreed-upon prices of additional drugs in the coming years. In response to an October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center that will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs using march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. It is unclear whether or how these selected models or similar policy initiatives will impact prescription drug pricing in the future, particularly in light of the recent U.S. presidential and congressional elections.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
reimbursed more favorably by government and other third-party payers than our medicines;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Acoramidis, patisiran, tafamidis, tafamidis meglumine and vutrisiran compete with WAINUA;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Plozasiran, pegozafermin and NST-1024 could compete with TRYNGOLZA and WAYLIVRA;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Lanadelumab-flyo, C1 esterase inhibitor, berotralstat, C1 esterase inhibitor subcutaneous, garadacimab, deucrictibant, NTLA-2002 and STAR-0215 could compete with donidalorsen;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Olpasiran, zerlasiran, lepodisiran and muvalaplin could compete with pelacarsen;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
VIR-2218, VIR-3434, BRII-179, AB-729, selgantolimod, bersacapavir, REP 2139-Mg and VTP-300 could complete with bepirovirsen;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Budesonide, sparsentan, atrasentan, iptacopan, zigakibart, sibeprenlimab, atacicept, ravulizumab, vemircopan, felzartamab, telitacicept and povetacicept could compete with sefaxersen; and
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
The FDA and foreign regulatory bodies have the authority to impose significant restrictions on an approved medicine through the product label and on advertising, promotional and distribution activities.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
choose to devote fewer resources to our medicines than it does to its own medicines.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
require us to verify the correctness of database contents and otherwise subject us to litigation or other liabilities.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedRisk Factors
Cybersecurity related events could include the deployment or use of harmful malware or malicious code, denial-of-service attacks, credential stuffing attacks, credential harvesting attacks, social engineering attacks (including deep fakes), fakes and phishing attacks), ransomware and other means to affect affect, as applicable, the confidentiality, privacy, security, integrity or availability of our data as well as information systems and infrastructure. infrastructure (including that of third parties with whom we work).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2021, 2025, we completed a $632.5 $770 million offering of 0% Notes due 2030 and used $319.0 $267.6 million of the net proceeds from the issuance of the 0% Notes due 2030 to repurchase the remaining $309.9 $200 million of our 1% Notes. 0% Notes due 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If government or other third-party payers fail to provide adequate coverage and payment rates for our medicines, including our commercial medicines and our medicines in development, or if healthcare reform measures increase our costs, decrease our sales, or negatively impact reimbursement for our products, our revenue will be limited.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in 2025, Novartis decided to return the clinical development program for a follow on to pelacarsen, and in 2022, Pfizer and Bayer decided to discontinue the clinical development programs for vupanorsen and fesomersen, respectively.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We must also continue to scale-up existing internal support functions to aid our commercialization efforts. efforts, which will need to work effectively in coordination with new commercial functional areas.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to effectively establish and or maintain marketing, sales, market access, distribution, and related functions, an effective commercialization infrastructure, or enter into agreements with third parties to commercialize our medicines, we may not be able to successfully commercialize our medicines.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
TRYNGOLZA is our first We currently have two independently launched medicine medicines, TRYNGOLZA and DAWNZERA, and we expect to independently launch additional medicines in the near future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our operations are subject to extensive legal and regulatory requirements affecting the health care industry, including federal federal, state, and state foreign fraud and abuse (including anti-kickback laws, laws and false claims laws, laws), transparency laws, such as the federal Sunshine Act, and health information privacy and security laws, which are subject to change at any time.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are not successful in executing this expansion, or if the demand for any of our commercial medicines exceeds our expectations, it could limit our ability to meet our manufacturing requirements and commercial objectives in the future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our obligations (including in relation to personal information obligations information) require us to implement and maintain certain practices, including those in relation to cross-border transfers of personal information. data.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have invested, and continue to invest, in the protection of our data and information technology systems and infrastructure, infrastructure as well as our compliance with relevant privacy and cybersecurity obligations, our efforts may not be successful.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Competition may negatively impact a partner’s focus on and commitment to our medicines and, as a result, could delay or otherwise negatively affect the commercialization of our medicines, including our commercial medicines and our medicines in development. partnered medicines.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We will also need to must ensure that we have the manufacturing capabilities in place to support advances in our drug development activities, such as new chemistries.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Since corporate partnering is part of our strategy to fund the advancement and commercialization of some of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our those drug development programs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Based on the minimum revenue thresholds we do not currently expect to fall within the scope of these requirements in the near term.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Commercial revenue in 2025 increased 49 percent compared to 2024. This increase was primarily driven by TRYNGOLZA product sales and higher royalty revenue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The remainder of our revenue came from programs under our R&D collaborations, including a $280 million upfront payment for the global license of sapablursen to Ono in the second quarter of 2025, reflecting the value that our pipeline and technology continues to generate.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Costs of sales for recently launched products, such as TRYNGOLZA and DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as R&D expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, H.R.1 - 119th Congress was signed into law, introducing significant changes to U.S. federal tax law. The new law restores current expensing of domestic R&D costs and allows us to accelerate the deduction for a significant amount of such costs we capitalized since 2022. These tax law changes did not have a material effect on our tax expense for the year ended December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
● Assessing the propriety of revenue recognition and associated deferred revenue;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
Commercial revenue in 2024 included new sources of commercial revenue with the launch of WAINUA in the U.S. in late January 2024 and the launch of TRYNGOLZA in the U.S. in late December 2024. SPINRAZA royalties in 2024 compared to 2023 were impacted from an annual order from a single country that did not recur in 2024.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
R&D revenue decreased in 2024 compared to 2023 primarily due to the decrease in WAINUA joint development revenue as development activities relating to ATTRv-PN wound down with the commercial launch of WAINUA. In addition, R&D revenue decreased due to the timing of significant partner payments.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
Interest expense for 2024 was $17.0 million compared to $12.7 million for 2023. In June 2023, we completed a $575.0 million offering of our 1.75% Notes and repurchased $504.4 million in principal of our 0.125% Notes. As a result, beginning in the second quarter of 2023, our interest expense related to our convertible notes included interest expense incurred for our 1.75% Notes. Interest expense in 2024 included a full year of interest expense related to our 1.75% Notes.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in income tax expense for 2024 compared to 2023 primarily related to the impact of the Royalty Pharma transaction in 2023. We reflected the Royalty Pharma transaction as a taxable sale, which required us to include the proceeds from the sale, net of currently deductible issuance costs, as taxable income in 2023.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 WAINUA $ 103.7 $ 115.5 TEGSEDI and WAYLIVRA 11.2 8.1 Eplontersen $87.6 $103.7 DAWNZERA 14.3 16.6 Olezarsen 87.1 147.4 138.3 Donidalorsen Zilganersen 13.9 7.6 Obudanersen 31.9 16.6 24.9 Zilganersen 7.6 8.4 Ulefnersen 11.1 15.0 10.8 Other development projects 89.9 101.0 81.1 84.5 Development overhead expenses 159.2 135.9 123.3 Total drug development, development expenses, excluding non-cash compensation expense related to equity awards 486.2 527.3 530.3 Non-cash compensation expense related to equity awards 42.5 41.2 34.5 Total drug development expenses $ 568.5 $ 564.8 $528.7 $568.5
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Contractual Obligations Payments Due by Period (in millions) (selected balances described below) Total Less than 1 year More than 1 year 0% Notes due 2030 (principal payable) $ 770.0 $- $770.0 1.75% Notes due 2028 (principal and interest payable) $ 610.3 $ 600.2 10.1 $ 600.2 590.1 0% Notes due 2026 (principal payable) 632.5 — 632.5 432.5 432.5 - Operating leases 260.3 20.9 239.4 484.8 35.5 449.3 Building mortgage payments (principal and interest payable) 9.6 9.1 0.5 9.1 8.6 Other obligations (principal and interest payable) 0.7 0.6 0.1 0.6 0.5 Total $ 1,513.4 $ 31.6 $ 1,481.8 2,297.2 $478.7 $1,818.5
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Personnel costs $ 31.4 $ 27.2 33.1 $31.4 Occupancy 31.1 28.5 28.7 Consulting 0.4 4.8 Patent expenses 5.3 4.3 Insurance 3.3 3.6 Computer software and licenses 14.4 8.4 2.7 Insurance 3.3 3.3 Patent expenses 6.4 5.3 Other 5.3 9.7 6.5 5.7 Total R&D support expenses, excluding non-cash compensation expense related to equity awards 94.8 82.6 81.0 Non-cash compensation expense related to equity awards 18.2 18.6 15.0 Total R&D support expenses $ 101.2 $ 96.0 113.0 $101.2
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our WAINUA joint development revenue in 2024 and 2023 includes included a $30 million milestone payment from AstraZeneca that we earned when the MHRA Medicines and Healthcare products Regulatory Agency, or MHRA, approved WAINUA for ATTRv-PN in the UK as WAINZUA and a $50 million milestone payment from AstraZeneca that we earned when the FDA approved WAINUA for ATTRv-PN in the U.S., respectively. WAINZUA.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
SG&A expenses, excluding non-cash compensation expense related to equity awards, increased in 2024 2025 compared to 2023 2024 primarily due to the launches of WAINUA TRYNGOLZA, DAWNZERA and TRYNGOLZA, including establishing the TRYNGOLZA field team in the second quarter of 2024, and advancing launch preparation activities for donidalorsen. WAINUA.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
From the time we were founded through December 31, 2024, 2025, we have raised net proceeds of approximately $2.6 $2.8 billion from the sale of our equity securities, which includes our sale of 11.5 million shares of common stock for net proceeds of $489 million in September 2024. securities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
SG&A expenses increased year over year primarily due to the launches of WAINUA TRYNGOLZA, DAWNZERA and TRYNGOLZA, including establishing the TRYNGOLZA field team in the second quarter of 2024, and advancing launch preparation activities for donidalorsen. WAINUA.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We recorded an income tax expense of $1.8 million for 2025 compared to an income tax benefit of $6.2 million for 2024 compared to an income tax expense of $32.3 million for 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Non-cash compensation expense related to equity awards increased in 2024 compared to 2023 were essentially flat year over year due to increased headcount and offset by a higher lower stock price on the grant date of annual equity awards in 2024 2025 compared to 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In 2023, 2025, we completed a $575.0 $770.0 million offering of our 1.75% 0% Notes due 2030 and used $488.2 $267.6 million of the net proceeds to repurchase $504.4 $200.0 million in principal of our 0.125% Notes. 0% Notes due 2026 at a premium.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Non-cash amortization of debt issuance costs $ 6.1 $ 5.9 6.3 $6.1 Interest expense payable in cash 10.1 10.5 6.4 Interest on mortgage for primary R&D and manufacturing facilities facility 0.4 0.4 Other 0.5 - Total interest expense $ 17.0 $ 12.7 17.3 $17.0
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
R&D support expenses, excluding non-cash compensation expense related to equity awards, were essentially flat increased in 2024 2025 compared to 2023. 2024 primarily due to increased costs relating to computer software and licenses.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new